论文部分内容阅读
目的对多西他赛作为一线用药治疗卵巢癌进行疗效及经济学的评价,为临床有效、经济的选择化疗方案提供参考。方法回顾性调查我院2008年3月至2011年2月住院的行多西他赛/卡铂化疗、紫杉醇/卡铂化疗及紫杉醇/卡铂化疗后多西他赛巩固治疗的卵巢癌初诊患者共35例250个疗程,分析比较3组的治疗成本、疗效及毒副作用。结果多西他赛/卡铂组、紫杉醇/卡铂组及多西他赛巩固治疗组有效率分别为91.7%、100%和88.9%(P>0.05),人均住院总费用分别为(75 106±21 232)、(137 053±8 530)和(186 051±21 938)元(P<0.01)。结论多西他赛作为一线用药治疗卵巢癌疗效稳定,耐受性好,费用最低。
Objective To evaluate the efficacy and economics of docetaxel as first-line drug in the treatment of ovarian cancer, and provide a reference for clinical effective and economical choice of chemotherapy. Methods A retrospective survey of newly diagnosed ovarian cancer patients undergoing docetaxel / carboplatin chemotherapy, paclitaxel / carboplatin chemotherapy and docetaxel consolidation after paclitaxel / carboplatin chemotherapy in our hospital from March 2008 to February 2011 was retrospectively reviewed. A total of 35 cases of 250 courses, analysis and treatment of three groups of cost, efficacy and side effects. Results The effective rates of docetaxel / carboplatin group, paclitaxel / carboplatin group and docetaxel group were 91.7%, 100% and 88.9% respectively (P> 0.05), and the total hospitalization costs per capita were (75 106 ± 21 232), (137 053 ± 8 530) and (186 051 ± 21 938) yuan (P <0.01). Conclusion Docetaxel is the first-line drug for the treatment of ovarian cancer with stable efficacy, good tolerability and lowest cost.